The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models
Y Pignochino, C Dell'Aglio, M Basiricò, F Capozzi… - Clinical Cancer …, 2013 - AACR
Clinical Cancer Research, 2013•AACR
Purpose: The multikinase inhibitor sorafenib displays antitumor activity in preclinical models
of osteosarcoma. However, in sorafenib-treated patients with metastatic-relapsed
osteosarcoma, disease stabilization and tumor shrinkage were short-lived and drug
resistance occurred. We explored the sorafenib treatment escape mechanisms to overcome
their drawbacks. Experimental Design: Immunoprecipitation, Western blotting, and
immunohistochemistry were used to analyze the mTOR pathway [mTOR complex 1 …
of osteosarcoma. However, in sorafenib-treated patients with metastatic-relapsed
osteosarcoma, disease stabilization and tumor shrinkage were short-lived and drug
resistance occurred. We explored the sorafenib treatment escape mechanisms to overcome
their drawbacks. Experimental Design: Immunoprecipitation, Western blotting, and
immunohistochemistry were used to analyze the mTOR pathway [mTOR complex 1 …
Abstract
Purpose: The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma. However, in sorafenib-treated patients with metastatic-relapsed osteosarcoma, disease stabilization and tumor shrinkage were short-lived and drug resistance occurred. We explored the sorafenib treatment escape mechanisms to overcome their drawbacks.
Experimental Design: Immunoprecipitation, Western blotting, and immunohistochemistry were used to analyze the mTOR pathway [mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)]. Cell viability, colony growth, and cell migration were evaluated in different osteosarcoma cell lines (MNNG-HOS, HOS, KHOS/NP, MG63, U-2OS, SJSA-1, and SAOS-2) after scalar dose treatment with sorafenib (10–0.625 μmol/L), rapamycin-analog everolimus (100–6.25 nmol/L), and combinations of the two. Cell cycle, reactive oxygen species (ROS) production, and apoptosis were assessed by flow cytometry. Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice injected with MNNG-HOS cells were used to determine antitumor and antimetastatic effects. Angiogenesis and vascularization were evaluated in vitro by exploiting endothelial branching morphogenesis assays and in vivo in xenografted mice and chorioallantoic membranes.
Results: After sorafenib treatment, mTORC1 signaling was reduced (downstream target P-S6), whereas mTORC2 was increased (phospho-mTOR Ser2481) in MNNG-HOS xenografts compared with vehicle-treated mice. Combining sorafenib with everolimus resulted in complete abrogation of both mTORC1 [through ROS-mediated AMP-activated kinase (AMPK) activation] and mTORC2 (through complex disassembly). The sorafenib/everolimus combination yielded: (i) enhanced antiproliferative and proapoptotic effects, (ii) impaired tumor growth, (iii) potentiated antiangiogenesis, and (iv) reduced migratory and metastatic potential.
Conclusion: mTORC2 activation is an escape mechanism from sorafenib treatment. When sorafenib is combined with everolimus, its antitumor activity is increased by complete inhibition of the mTOR pathway in the preclinical setting. Clin Cancer Res; 19(8); 2117–31. ©2013 AACR.
AACR